Literature DB >> 27920180

Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.

Adam D DeZure1, Nina M Berkowitz1, Barney S Graham1, Julie E Ledgerwood1.   

Abstract

Chikungunya virus (CHIKV) is a global public health threat, having been identified in >60 countries in Asia, Africa, Europe, and the Americas. There is no cure for or licensed vaccine against CHIKV infection. Initial attempts at CHIKV vaccine development began in the early 1960s. Whole-inactivated and virus-like particle (VLP) vaccines are 2 of the current approaches being evaluated. Success of these approaches is dependent on a safe, well-tolerated vaccine that is immunogenic and deployable in regard to manufacturing, stability, and delivery characteristics. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  alphavirus; chikungunya virus; vaccine; virus-like particle vaccine; whole-inactivated vaccine

Mesh：

Substances：

Year:  2016        PMID： 27920180      PMCID： PMC5137244          DOI： 10.1093/infdis/jiw352

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  37 in total

1.  Comparative immunogenicities of chikungunya vaccines prepared in avian and mammalian tissues.

Authors:  V R Harrison; L N Binn; R Randall
Journal:  Am J Trop Med Hyg       Date:  1967-11       Impact factor: 2.345

2.  A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.

Authors:  Samantha Brandler; Claude Ruffié; Chantal Combredet; Jean-Baptiste Brault; Valérie Najburg; Marie-Christine Prevost; André Habel; Erich Tauber; Philippe Desprès; Frédéric Tangy
Journal:  Vaccine       Date:  2013-06-04       Impact factor: 3.641

3.  Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.

Authors:  Katrin Ramsauer; Michael Schwameis; Christa Firbas; Matthias Müllner; Robert J Putnak; Stephen J Thomas; Philippe Desprès; Erich Tauber; Bernd Jilma; Frederic Tangy
Journal:  Lancet Infect Dis       Date:  2015-03-02       Impact factor: 25.071

4.  A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.

Authors:  Karthik Mallilankaraman; Devon J Shedlock; Huihui Bao; Omkar U Kawalekar; Paolo Fagone; Aarthi A Ramanathan; Bernadette Ferraro; Jennifer Stabenow; Paluru Vijayachari; Senthil G Sundaram; Nagarajan Muruganandam; Gopalsamy Sarangan; Padma Srikanth; Amir S Khan; Mark G Lewis; J Joseph Kim; Niranjan Y Sardesai; Karuppiah Muthumani; David B Weiner
Journal:  PLoS Negl Trop Dis       Date:  2011-01-11

5.  Chikungunya virus vaccine prepared by Tween-ether extraction.

Authors:  K H Eckels; V R Harrison; F M Hetrick
Journal:  Appl Microbiol       Date:  1970-02

6.  Prime-boost immunization strategies against Chikungunya virus.

Authors:  David Hallengärd; Fok-Moon Lum; Beate M Kümmerer; Aleksei Lulla; Valeria Lulla; Juan García-Arriaza; John K Fazakerley; Pierre Roques; Roger Le Grand; Andres Merits; Lisa F P Ng; Mariano Esteban; Peter Liljeström
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

7.  Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus.

Authors:  Mugdha Tiwari; Manmohan Parida; S R Santhosh; Mohsin Khan; Paban Kumar Dash; P V Lakshmana Rao
Journal:  Vaccine       Date:  2009-02-27       Impact factor: 3.641

8.  Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

Authors:  Ana Maria Henao-Restrepo; Ira M Longini; Matthias Egger; Natalie E Dean; W John Edmunds; Anton Camacho; Miles W Carroll; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Stefanie Hossmann; Mandy Kader Kondé; Souleymane Kone; Eeva Kuisma; Myron M Levine; Sema Mandal; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; Conall H Watson; Sakoba Kéïta; Marie Paule Kieny; John-Arne Røttingen
Journal:  Lancet       Date:  2015-08-03       Impact factor: 79.321

9.  Inactivation of Chikungunya virus by 1,5 iodonapthyl azide.

Authors:  Anuj Sharma; Paridhi Gupta; Radha K Maheshwari
Journal:  Virol J       Date:  2012-12-04       Impact factor: 4.099

10.  Effective chikungunya virus-like particle vaccine produced in insect cells.

Authors:  Stefan W Metz; Joy Gardner; Corinne Geertsema; Thuy T Le; Lucas Goh; Just M Vlak; Andreas Suhrbier; Gorben P Pijlman
Journal:  PLoS Negl Trop Dis       Date:  2013-03-14
View more
  12 in total

Review 1.  Development of Vaccines for Chikungunya Fever.

Authors:  Jesse H Erasmus; Shannan L Rossi; Scott C Weaver
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

2.  Detection, isolation, and characterization of chikungunya viruses associated with the Pakistan outbreak of 2016-2017.

Authors:  Si-Qing Liu; Xiao Li; Ya-Nan Zhang; Ai-Li Gao; Cheng-Lin Deng; Jun-Hua Li; Shoukat Jehan; Nadia Jamil; Fei Deng; Hongping Wei; Bo Zhang
Journal:  Virol Sin       Date:  2017-12-21       Impact factor: 4.327

3.  An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses.

Authors:  Ningning Ge; Jin Sun; Zhihua Liu; Jiayi Shu; Huimin Yan; Zhihua Kou; Yu Wei; Xia Jin
Journal:  Virol Sin       Date:  2022-01-28       Impact factor: 6.947

Review 4.  Vaccines for epidemic infections and the role of CEPI.

Authors:  Stanley A Plotkin
Journal:  Hum Vaccin Immunother       Date:  2017-04-04       Impact factor: 3.452

Review 5.  Recent progress on chikungunya virus research.

Authors:  Wenxi An; Ningning Ge; Yilin Cao; Jin Sun; Xia Jin
Journal:  Virol Sin       Date:  2017-11-28       Impact factor: 4.327

Review 6.  Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus.

Authors:  Chean Yeah Yong; Hui Kian Ong; Swee Keong Yeap; Kok Lian Ho; Wen Siang Tan
Journal:  Front Microbiol       Date:  2019-08-02       Impact factor: 5.640

Review 7.  Recent Progress in Vaccine Development Against Chikungunya Virus.

Authors:  Shan Gao; Siqi Song; Leiliang Zhang
Journal:  Front Microbiol       Date:  2019-12-19       Impact factor: 5.640

8.  Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology.

Authors:  Preethi Eldi; Tamara H Cooper; Liang Liu; Natalie A Prow; Kerrilyn R Diener; Paul M Howley; Andreas Suhrbier; John D Hayball
Journal:  Mol Ther       Date:  2017-07-15       Impact factor: 11.454

Review 9.  Cellular and Molecular Immune Response to Chikungunya Virus Infection.

Authors:  Ithallo S B Tanabe; Eloiza L L Tanabe; Elane C Santos; Wanessa V Martins; Isadora M T C Araújo; Maria C A Cavalcante; Ana R V Lima; Niels O S Câmara; Leticia Anderson; Dinar Yunusov; Ênio J Bassi
Journal:  Front Cell Infect Microbiol       Date:  2018-10-10       Impact factor: 5.293

Review 10.  Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials.

Authors:  Fatemeh Oroojalian; Ali Haghbin; Behzad Baradaran; Nima Hemmat; Mohammad-Ali Shahbazi; Hossein Bannazadeh Baghi; Ahad Mokhtarzadeh; Michael R Hamblin
Journal:  Int J Biol Macromol       Date:  2020-09-28       Impact factor: 6.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.